Lilly plans to enroll up to 140 participants with the study expected to be completed next year. Liver disease Novo's Wegovy ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

Wall Street held near its record heights Monday, ahead of a week likely to be dominated by updates from the head of the ...

Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from the head of the ...

BANGKOK — World shares were mixed on Tuesday after Wall Street held near its records, with traders awaiting fresh cues about ...

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis ...